Phenotype-Driven Selection

Matches initial pharmacotherapy to clinical specifiers (e.g., anxious distress, insomnia, psychomotor slowing, chronic pain) while filtering against organ contraindications, hepatic/renal clearance, and pregnancy/lactation safety.

Closed-Loop Measurement Care

Integrates baseline PHQ-9 scoring with longitudinal follow-up nodes, automating response rate calculations (≥50% response vs. remission vs. pseudo-resistance).

Actionable Next Steps

Eliminates clinical guesswork by generating exact cross-titration schedules, washout intervals, evidence-backed augmentation regimens, and structured SBAR referral summaries.

Stage 1: Phenotyping & Intake Screener

• Interactive PHQ-9 Matrix: Rapidly score the 9 DSM-5 depression criteria. Scores ≥10 confirm criteria for pharmacotherapy; scores <10 prompt active surveillance or psychotherapeutic interventions.
• Item 9 Safety Guardrail: Endorsement of suicidal ideation (Item 9 ≥1) immediately flags crisis pathways and launches evidence-based safety evaluation protocols (C-SSRS / Stanley-Brown Safety Plan).
• Safety & Comorbidity Filters: Filter candidates across organ risks (prolonged QTc, hepatic impairment, seizure disorders, uncontrolled hypertension) and perinatal status (pregnancy and lactation compatibility).

Stage 2: Antidepressant Selection

• Algorithmic Match Scoring: View dynamic suitability scores across first- and second-line agents (SSRIs, SNRIs, NDRIs, NaSSAs, SMS/SARIs).
• Pharmacological & Tolerability Profiling: Review side-effect burdens at a glance with 5-point mini-meter chips evaluating sexual dysfunction, metabolic/weight gain risk, sedation, insomnia, GI distress, and discontinuation/withdrawal syndrome.
• Side-by-Side Comparison: Compare receptor binding profiles (Ki affinities for SERT, NET, DAT, 5-HT2A, H1, and M1) and dosing parameters.

Stage 3: Longitudinal Tracking & Optimization

• Trajectory vs. Clinical Thresholds: Plot longitudinal follow-up scores (Weeks 2, 4, 6, 8, 12) against projected benchmark curves and clinical cutoffs.
• Automated Status Stratification: Categorizes patients into Remission (PHQ-9 <5), Full Response (≥50% drop), Partial Response (25–49%), or Inadequate Response (<25%).
• Decision Branching: Direct cross-taper schedules, direct switches, or mandatory washout intervals alongside Level-1 and Level-2 augmentation protocols (Aripiprazole, Bupropion, Lithium, Esketamine).

Stage 4: Psychiatric Escalation & SBAR Referral

• 4-Tier Escalation Model: Identify criteria for specialized outpatient referral, intensive outpatient programs (IOP/PHP), or acute emergency crisis intervention.
• EHR-Ready SBAR Export: Instantly compile the patient’s intake metrics, failed trials, current dosing, and clinical rationale into a structured SBAR (Situation, Background, Assessment, Recommendation) note ready to paste into the chart.